Table 3.
Estimates of treatment effects on secondary endpoints
| Placebo (n=214) | Brensocatib (n=190) | Unadjusted effect estimate (95% CI) | Adjusted*effect estimate (95% CI) | ||
|---|---|---|---|---|---|
| 28 day mortality†, n (%) | 23 (11%) | 29 (15%) | 1·44 (0·83–2·48) | 1·41 (1·06–1·88) | |
| Clinical improvement | |||||
| Patients improved, n (%) | 186 (87%) | 159 (84%) | .. | .. | |
| Time to clinical improvement† | .. | .. | 0·87 (0·70–1·07) | 0·87 (0·76–1·00) | |
| Discharge or UK National Early Warning Score <2† | |||||
| Patients discharged or with UK National Early Warning Score ≤2, n (%) | 195 (91%) | 172 (91%) | .. | .. | |
| Time to discharge or UK National Early Warning Score <2† | .. | .. | 0·98 (0·79–1·21) | 0·98 (0·84–1·13) | |
| Oxygen use and ventilation | |||||
| Oxygen-free days‡ | 24·5 (17·0–27·0) | 24·0 (11·0–27·0) | 0·93 (0·78–1·12), | 0·93 (0·87–0·99) | |
| Duration of new oxygen use‡ | 0·0 (0·0–1·0) | 0·0 (0·0–2·0) | 1·15 (0·39–3·38) | 1·13 (0·73–1·74) | |
| Ventilation-free days§ | 28·0 (26·0–28·0) | 28·0 (22·0–28·0) | 0·85 (0·55–1·30) | 0·84 (0·69–1·04) | |
| Duration of new ventilation use‡ | 0·0 (0·0–0·0) | 0·0 (0·0–0·0) | 1·64 (0·69–3·92) | 1·68 (1·09–2·58) | |
| Mechanical ventilation-free days§ | 28·0 (28·0–28·0) | 28·0 (28·0–28·0) | 0·77 (0·46–1·29) | 0·77 (0·59–1·01) | |
| Duration of new mechanical ventilation use‡ | 0·0 (0·0–0·0) | 0·0 (0·0–0·0) | 1·22 (0·30–4·86) | 1·32 (0·68–2·56) | |
| Duration of hospitalisation‡ | 5·0 (3·0–11·0) | 6·0 (3·0–10·5) | 1·03 (0·84–1·26) | 1·03 (0·92–1·15) | |
Data are median number of days (IQR), unless otherwise specified. Duration of ventilation use includes non-invasive and invasive mechanical ventilation.
*
Adjusted for minimisation variables; age and site as a random effect.
†
Hazard ratio from Cox proportional hazards model.
‡
Incidence rate ratio from negative binomial regression.
§
Odds ratio from ordinal logistic regression model.